Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 13, 2021

Primary Completion Date

September 15, 2026

Study Completion Date

September 15, 2027

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

Ibrutinib and obinutuzumab

Patients will receive fixed-duration treatment with ibrutinib and obinutuzumab.

Trial Locations (1)

RECRUITING

Strategic Research Program on CLL, Milan

All Listed Sponsors

lead

Paolo Ghia

OTHER